ERAS - Erasca, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$17.80
DETAILS
HIGH:
$30.00
LOW:
$10.00
MEDIAN:
$12.00
CONSENSUS:
$17.80
UPSIDE:
58.36%
About Erasca, Inc. (https://www.erasca.com)
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jonathan E. Lim | Co-Founder, Chairman & Chief Executive Officer | 1972 | $1,163,588 USD |
| David Chacko | Chief Financial Officer & Chief Business Officer | 1984 | $775,216 USD |
| Shannon Morris | Chief Medical Officer | 1970 | $772,700 USD |
| Ebun S. Garner | Chief Legal Officer & Corporate Secretary | 1972 | $607,440 USD |
| Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | 1958 | $93,181 USD |
| Alison Tjosvold Milhous | Senior Vice President of Accounting | 1979 | – |
| Brian L. Baker | Senior Vice President of Finance | 1967 | – |
| Chandra D. Lovejoy | Chief Regulatory Affairs Officer | 1971 | – |
| Dawei Xuan | Senior Vice President of Clinical Pharmacology | – | – |
| Lisa Tesvich-Bonora | Chief People Officer | – | – |
| Minli Xie | Senior Vice President of Pharmaceutical Development & Operations | – | – |
| Nik Chetwyn | Chief Operating Officer | – | – |
| Robert Shoemaker | Chief Scientific Officer | 1981 | – |